Unity biotechnology, inc. (UBX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Contribution revenue

-

-

1,382

-

Operating expenses:
Research and development

70,957

58,907

37,373

13,707

General and administrative

20,046

16,016

9,617

5,137

Change in fair value of contingent consideration

-1,352

4,542

-

-

Total operating expenses

89,651

79,465

46,990

18,844

Loss from operations

-89,651

-79,465

-45,608

-18,844

Loss on extinguishment of promissory notes

-

-

-

-9,377

Interest income

3,289

3,312

1,055

-2,183

Other expense, net

4,185

-245

-103

-

Net loss

-82,177

-76,398

-44,656

-30,404

Other comprehensive loss
Unrealized gain on marketable debt securities, net of tax

185

9

-104

-

Comprehensive loss

-81,992

-76,389

-44,760

-30,404

Net loss per share, basic and diluted

-1.88

-2.70

-13.97

-11.42

Weighted average number of shares used in computing net loss per share, basic and diluted

43,624

28,269

3,197

2,662